Sean McCarthy (CytomX)
March 24, 2020 06:33 AM EDTUpdated 11:48 AM
Deals
Discovery

Astel­las em­pow­ers new­ly en­er­gized Cy­tomX with $80M up­front to get pre­clin­i­cal bis­pe­cif­ic work go­ing

Amber Tong

In the lat­est up­swing on the Cy­tomX roller coast­er ride, Astel­las is stok­ing the wan­ing flames of its plat­form tech with

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

A service from the Financial Times